The European Union has awarded EURE-CART (EURopean Endeavour for Chimeric Antigen Repector Therapies) with 5 Million Euro within the Horizon 2020 – Research and Innovation Framework Programme, section reserved to the new therapies for chronic diseases (including cancer).

To carry out this project and to reach clinical translation, a consortium of nine partners from five different EU countries has been established. acromion GmbH is one of these nine partners.

EURE-CART will bring together clinical experts in oncology, and pioneers and leaders in the field of cell and gene therapy for conducting a first-in-man Phase I/II clinical trial

Bio Korea 2018

acromion@biokorea2018 It’s been an exciting pleasure to be in Seoul and meet up for updates, networking and sharing ideas. Thank you all and looking forward seeing you at the next opportunity!